Upadacitinib

Indication

For treating moderately to severely active ulcerative colitis - Nice TA856

NICE TA 865 - Upadacitinib for treating moderately to severely active ulcerative colitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Red

Brand:

Rinvoq

Nice TA:

856

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Gastro-intestinal system

Background

1.1 Upadacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults:

when conventional or biological treatment cannot be tolerated, or
if the condition has not responded well enough or has stopped responding to these treatments, and
if the company provides upadacitinib according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 15 - Feb - 2023

Breadcrumb

Upadacitinib

Indication

Background

Recommendation

Decisions of Lancashire local decision making groups